Developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives. We are committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.

FierceBiotech Names Voyager Therapeutics as one of its “Fierce 15” Biotech Companies of 2014

Read the Press Release Read the Story From Fierce 15

September 3, 2014

Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer